Clinical trial
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
NCT00244881 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00244881 |
|---|---|
| Title | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) |
| Official title | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 26 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 27, 2005 |
| Last update posted | Dec 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: